Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.

Details

Language :

English

ISSN :

13696998

Database :

Complementary Index

Journal :

Journal of Medical Economics

Publication Type :

Academic Journal

Accession number :

132718327

Full Text :

https://doi.org/10.1080/13696998.2018.1542599